Clostridium difficile infection (CDI) is a significant cause of morbidity and mortality. Disease related to CDI ranges from asymptomatic colonization to mild diarrheal disease to severe pseudomembranous colitis. Despite the extensive characterization of the histologic lesions associated with C. difficile infection, virtually nothing is known mechanistically about the contribution of host factors in disease. It is likely that some of the clinical differences encountered in infected individuals are due to variation in host response to colonization with C. difficile. We hypothesize that variation in the host innate and adaptive responses for C. difficile are in part responsible for the different clinical phenotypes that are seen in the setting of CDI. Furthermore, we speculate that these variable responses reflect underlying genetic and possibly epigenetic differences in the host. To address these hypotheses we propose the following specific aims: In the first aim we will characterize the innate and adaptive immune response to C. difficile colonization and determine the role of this response in determining the disease manifestations. In the second aim we will identify serum fecal biomarkers and epigenetic changes that correlate distinct clinical outcomes.
This aim will examine samples obtained from the Project area #1 for this purpose.
The third aim will examine the interaction between host genetics/immune response and C. difficile genotype in the pathogenesis of disease. Mice with defined differences in host response will be challenged with C. difficile strains generated and characterized from the human studies in Project area #1. This will provide an examination ofthe relative contribution of host and pathogen factors in disease. These experiments will increase our understanding ofthe host and microbial mechanisms of C. difficile-induced colonic inflammation vs. asymptomatic colonization and identify biomarkers that can be used to improve clinical treatments and outcomes.
Clostridium difficile infection is associated with the development of severe inflammation of the large intestine, resulting in significant morbidity and mortality. Our objective is to understand the mechanisms of this inflammation and identify biomarkers that can be used to improve clinical treatments and outcomes.
|Kopliku, Fatos A; Schubert, Alyxandria M; Mogle, Jill et al. (2015) Low prevalence of Clostridium septicum fecal carriage in an adult population. Anaerobe 32:34-6|
|Leslie, Jhansi L; Young, Vincent B (2015) The rest of the story: the microbiome and gastrointestinal infections. Curr Opin Microbiol 23:121-5|
|Seekatz, Anna M; Young, Vincent B (2014) Clostridium difficile and the microbiota. J Clin Invest 124:4182-9|
|Islam, J; Taylor, A L; Rao, K et al. (2014) The role of the humoral immune response to Clostridium difficile toxins A and B in susceptibility to C. difficile infection: a case-control study. Anaerobe 27:82-6|
|Rao, Krishna; Young, Vincent B; Aronoff, David M (2014) Fecal microbiota therapy: ready for prime time? Infect Control Hosp Epidemiol 35:28-30|
|Theriot, Casey M; Koenigsknecht, Mark J; Carlson Jr, Paul E et al. (2014) Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat Commun 5:3114|
|El-Zaatari, Mohamad; Chang, Yu-Ming; Zhang, Min et al. (2014) Tryptophan catabolism restricts IFN-?-expressing neutrophils and Clostridium difficile immunopathology. J Immunol 193:807-16|
|Huang, A M; Marini, B L; Frame, D et al. (2014) Risk factors for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients. Transpl Infect Dis 16:744-50|
|Schloss, Patrick D; Iverson, Kathryn D; Petrosino, Joseph F et al. (2014) The dynamics of a family's gut microbiota reveal variations on a theme. Microbiome 2:25|
|Marino, Simeone; Baxter, Nielson T; Huffnagle, Gary B et al. (2014) Mathematical modeling of primary succession of murine intestinal microbiota. Proc Natl Acad Sci U S A 111:439-44|
Showing the most recent 10 out of 42 publications